Kura Oncology is a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers. The Company's lead product candidate, tipifarnib, is a potent, selective and orally bioavailable inhibitor of farnesyl transferase. Tipifarnib is a new chemical entity, or NCE, and a member of a class of product candidates called farnesyl transferase inhibitors, or FTIs. Protein farnesylation is a key cell signaling process implicated in various cancer processes, including survival, growth and proliferation of tumor cells.
|HQ||San Diego, US|
|Size (employees)||34 (est)+14%|
Net income (Q3, 2018)
Market capitalization (12-Dec-2018)
Closing stock price (12-Dec-2018)
|USD||Q3, 2013||Q1, 2014||Q2, 2014||Q2, 2015||Q3, 2015||Q1, 2016||Q2, 2016||Q3, 2016||Q1, 2017||Q2, 2017||Q3, 2017||Q1, 2018||Q2, 2018||Q3, 2018|
General and administrative expense
Operating expense total
|USD||Q3, 2013||Q1, 2014||Q2, 2014||Q3, 2015||Q1, 2016||Q2, 2016||Q3, 2016||Q1, 2017||Q2, 2017||Q3, 2017||Q1, 2018||Q2, 2018||Q3, 2018|
Phase II Trials Products
Preclinical Phase Products
When was Kura Oncology founded?
Kura Oncology was founded in 2007.
How many employees does Kura Oncology have?
Kura Oncology has 34 employees.
Who are Kura Oncology competitors?
Competitors of Kura Oncology include Inventiva, BioInvent and Orion.
Where is Kura Oncology headquarters?
Kura Oncology headquarters is located at 125 11119 N Torrey Pines Rd, San Diego.
Where are Kura Oncology offices?
Kura Oncology has an office in San Diego.
How many offices does Kura Oncology have?
Kura Oncology has 1 office.